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AbstrAct
Histological analysis of liver tissue continues to 
play an important role in modern hepatological 
practice. This review explores the indications for 
medical liver biopsy in addition to the procedure 
itself, potential complications, preparation of 
tissue and routine staining. A broad selection of 
histological images is included to illustrate the 
appearance of liver tissue both in health and in 
several important diseases.
IntroductIon
Liver biopsy continues to play an impor-
tant role in modern clinical practice. Biop-
sies can be ‘targeted’ (surgical) at a lesion 
or ‘non-targeted’ (medical) to allow assess-
ment of the liver parenchyma in general. 
This review discusses indications for 
medical liver biopsy, the procedure itself, 
possible complications, sample prepara-
tion, staining and histological findings both 
in normal liver tissue and in several impor-
tant diseases. A familiarity with histological 
appearances can improve understanding of 
pathophysiology and underpins good clin-
ical decision-making. We have endeavoured 
to provide high-quality images to support 
the descriptions given.
IndIcAtIons for performIng A 
lIver bIopsy
The advent of non-invasive tools such as 
serum biomarkers and elastography has 
given clinicians additional tools for esti-
mating the severity of fibrosis.1 While this 
has resulted in reduced overall need for 
liver biopsy, histological analysis of the 
hepatic parenchyma remains an important 
investigation.
Broadly, the indications for medical liver 
biopsy fall into two groups. First, estab-
lishing a diagnosis, which includes ruling 
out other diagnoses or determining the 
predominant pathology if more than one 
cause of liver injury is present. Second, liver 
biopsy allows assessment of disease severity 
including staging and grading.2 Staging 
pertains to the severity of fibrosis: although 
non-invasive tests increasingly have a role 
to play, biopsy is generally considered the 
‘gold-standard’ test provided a satisfac-
tory sample is obtained. Grading involves 
determining the severity of the underlying 
disease process.
Biopsies are occasionally carried out in 
acute liver failure. Biopsy in this setting 
would be determined on a case-by-case 
basis; recent guidance suggests that it 
can be considered to rule out infiltrative 
malignancy, alcohol-related pathology 
and cirrhosis.3
performIng A lIver bIopsy
Liver biopsies are usually obtained via a 
percutaneous approach using ultrasound 
guidance. Coagulopathy and thrombocy-
topenia are common problems in patients 
with liver disease and may pose an unac-
ceptable risk for a percutaneous approach: 
in these cases, a trans-venous approach 
can be used instead, avoiding puncture of 
the liver capsule.4
For a trans-venous approach, the internal 
jugular vein is normally used to introduce 
a catheter into one of the hepatic veins 
under fluoroscopic guidance,5 and a biopsy 
needle is then advanced. This approach 
reduces the risk of significant bleeding, 
although the core of tissue obtained may be 
smaller and multiple needle passes needed.6 
Other reasons for a trans-venous approach 
include ascites, simultaneous acquisition 
of a hepatic venogram or pressure studies 
and obesity or other anatomical consider-
ations where a safe percutaneous puncture 
site cannot be identified. Biopsies can be 
obtained laparoscopically, although this is 
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Table 1 Summary of the routine stains used for a medical liver biopsy in addition to H&E
Stain Material stained Relevance in liver biopsy
Reticulin Type III collagen fibres Useful for assessing gross architecture of the specimen. Condensation of reticulin fibres is seen in areas 
of recent hepatocellular necrosis and in fibrosis
Also useful for highlighting nodular changes in nodular regenerative hyperplasia
Haematoxylin van 
Gieson*
Type I collagen fibres Normally only present in portal tracts and around hepatic veins; increased staining seen in fibrosis
Orcein Hepatitis B surface antigen May be present in chronic Hepatitis B infection
Copper-associated protein Can be increased in any cause of chronic cholestasis and Wilson’s disease
Elastic fibres Produced in longstanding fibrosis and can help differentiate this from recent architectural changes 
caused by necrosis and collapse
Periodic acid–Schiff Glycogen Stains hepatocytes which contain abundant glycogen, useful to both detect hepatocytes and show 
their absence (for example in confluent necrosis)
Periodic acid–Schiff 
diastase
Mucin
Alpha-1 antitrypsin
Following the digestion of glycogen with diastase abnormal polymers of alpha-1 antitrypsin can be 
seen in cases of alpha-1 antitrypsin deficiency
Perls’ stain Haemosiderin (ferric iron) Increased iron deposition is seen in any cause of iron overload
*Other stains such as Sirius red and trichrome may also be used to visualise collagen fibres.
not routine in the UK and is often opportunistic due to 
the presence of a macroscopically abnormal liver.
In general, use of a 16G or wider cutting needle is 
recommended for liver biopsy. The presence of 10–12 
portal tracts within the specimen is considered suffi-
cient for reliable analysis,7 ensuring that architectural 
relationships between structures are maintained. The 
length of the biopsy specimen correlates with the 
number of portal tracts,8 and therefore a length of 
20–25 mm is preferred. Specimens which are subop-
timal in size may result both in diagnostic inaccuracy 
and in the inaccurate assessment of disease severity.7
potentIAl complIcAtIons
Liver biopsies are usually carried out as a day-case 
admission, with bed rest and basic non-invasive moni-
toring following the procedure. Overnight admission 
may be warranted if the patient lives alone. Postproce-
dural pain is usually mild.9 The most significant risk is 
bleeding—this is often immediate but can present up 
to 1 week after the procedure.10 Other risks include 
haemobilia, non-hepatic organ puncture, infection and 
reaction to local anaesthetic.
Severe bleeding following a percutaneous liver biopsy 
is usually intraperitoneal and haemodynamic insta-
bility is common.7 A UK-wide audit in 2013 reported 
a risk of clinically significant bleeding (with drop in 
blood count, radiological evidence of bleeding and 
requirement for intervention) of 0.4%. The mortality 
rate was 0.11%,11 with bleeding the cause in all cases. 
It is worth highlighting that targeted biopsy was linked 
to a greater risk of major complications than non-tar-
geted biopsy.
stAInIng
Liver biopsy specimens are fixed in formalin to 
form cross-links and prevent degradation. Speci-
mens are then dehydrated and embedded in paraffin 
before microtome sectioning and mounting on slides. 
Non–formalin-fixed tissue may be needed for tests 
such as microbiological analysis or copper quantifi-
cation studies.7 The standard initial stain is H&E,12 
which stains nuclei blue and cytoplasm and fibrous 
tissue pink. Other routine stains carried out are listed 
below in table 1.13 Immunohistochemistry is used in 
particular situations, some of which are mentioned in 
the relevant sections later in the article.
HIstologIcAl Assessment
In a medical liver biopsy, the normal liver architec-
ture should be maintained unless there are marked 
morphological changes due to cirrhosis or necrosis. 
Usually areas of hepatic parenchyma with hepatocytes 
and sinusoids are seen (‘lobular’ region), which are 
interspersed with central venules and portal tracts. 
Portal tracts usually contain a portal vein, a branch of 
the hepatic artery and a bile duct.13
Three different ‘zones’ are defined by these struc-
tures, although the anatomy is complex: zone 1 is adja-
cent to the portal tract, zone 3 is closest to the hepatic 
venule and zone 2 is in between (see figure 1). This 
arrangement of structures is also called an ‘acinus’.12
fIbrosIs
Fibrosis is a dynamic process caused by chronic injury, 
inflammation and regeneration. This usually begins in 
a particular area (eg, zone 1 in chronic biliary disease) 
and extends outwards as thin fibrous septa. These can 
then extend to adjacent portal tracts or central venules 
which is known as bridging fibrosis,12 a precursor to 
cirrhosis. As the process advances further, the cirrhotic 
changes of distortion and nodule formation ensue. The 
use of stains (eg, HvG and orcein—see table 1) can help 
to distinguish the presence of long-standing fibrosis, 
which is associated with the formation of mature 
elastic fibres, from the collapse of normal architecture 
which can be seen in acute hepatitis with necrosis.13
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Figure 1 Reticulin stain showing normal liver parenchyma with a portal tract in the top left of the image (P) and a central vein in the bottom 
right (V). Zones 1–3 are labelled.
Figure 2 Top left—haematoxylin van Gieson (HvG) stain showing mild zone 3 steatosis without fibrosis, in which collagen fibres (pink–red, 
arrow) are confined to portal tracts (P). Top right—HvG stain showing steatohepatitis with mild fibrosis in the form of fibrous expansion (arrow) 
of the portal tract (P). Note the presence of steatosis (S). Bottom left—HvG stain showing steatohepatitis with moderate fibrosis, with thin fibrous 
bridges (arrow) linking adjacent portal tracts (P). Bottom right—HvG stain showing steatohepatitis with established cirrhosis, with thick bands of 
fibrosis (arrows) encircling a hepatocyte nodule.
Figure 2 shows the spectrum of fibrosis within the 
context of fatty liver disease from steatosis without 
fibrosis to mild fibrosis, moderate fibrosis (with 
bridging) and established cirrhosis.
fAtty lIver dIseAse
Fatty liver is defined by an abnormal deposition of fat 
(or steatosis) within more than 5% of hepatocytes14—
this is best appreciated in figure 2. The two most 
common causes of fatty liver are excessive alcohol 
consumption and in association with insulin resistance 
and the metabolic syndrome (non-alcoholic fatty liver 
disease, NAFLD). Other causes include drugs, coeliac 
disease, parenteral nutrition, starvation and HIV. Stea-
tosis alone does not necessarily have any significant 
sequelae; however, inflammation (steatohepatitis) may 
result which can lead to fibrosis.
Biopsies are undertaken in both alcohol-related and 
non–alcohol-related aetiologies of fatty liver disease, 
although importantly it is usually not possible to tell 
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Figure 3 Top left—H&E stain showing scattered large and medium-size droplet steatosis and hepatocyte ballooning in the centre of the field, 
composed of a hepatocyte (H) with swollen optically clear cytoplasm containing a Mallory-Denk body. Top right—Perls’ stain showing heavy iron 
deposition in hepatocytes and biliary epithelium (a bile duct is present in the centre of the image) in the context of HFE haemochromatosis. Bottom 
right—PAS-D stain showing numerous PAS-D-positive globules within hepatocyte cytoplasm, adjacent to a portal tract (bottom centre of image). 
Globules tend to be concentrated in periportal hepatocytes. Bottom left—H&E stain showing typical changes of Budd-Chiari syndrome with dilated 
and relatively empty sinusoids, with numerous red blood cells translocated into the space of Disse (arrows).
the two aetiologies apart histologically.12 In alcohol-re-
lated liver disease, biopsy may be considered in cases 
of diagnostic uncertainty or to accurately stage the 
disease.15 Liver biopsy used to be recommended in the 
context of severe alcoholic hepatitis to both confirm 
the presence of steatohepatitis and rule out other 
causes of liver injury; however, recent international 
guidelines and general opinion may be shifting away 
from this approach.15 16
Biopsy in NAFLD is usually undertaken to ascertain 
whether significant fibrosis is present. Typically, this 
need arises when biomarkers or elastography suggest 
advanced fibrosis (these tests perform less well at 
‘ruling in’ advanced fibrosis in this context than ‘ruling 
out’1) or are discordant.17 The biopsy may also reveal 
findings of non-alcoholic steatohepatitis (NASH)—a 
risk factor for disease and fibrosis progression.18 It is 
worth noting that NASH can only be diagnosed with 
a liver biopsy and describes the presence of steatosis, 
ballooning and lobular inflammation (with or without 
fibrosis); less severe histological changes would be 
termed non-alcoholic fatty liver (NAFL) and confer a 
lower risk of disease progression.
The inflammation in steatohepatitis is usually more 
lobular than portal which, if excessive, may signify an 
additional process (although children/adolescents with 
NASH can have a more portal distribution).14 Mono-
nuclear cells are commonly seen, and neutrophils are 
perhaps more common in alcoholic steatohepatitis and 
can circle hepatocytes termed ‘satellitosis’.12 Ballooning 
of hepatocytes is seen, where they swell and increase in 
size with disruption of the cytoskeleton. Mallory-Denk 
bodies are typically found within the cytoplasm of 
ballooned hepatocytes—these are inclusion bodies 
comprised of cytokeratin with a ‘twisted rope’ appear-
ance.19 Immunohistochemical staining for cytokeratin 
and ubiquitin can be used to highlight Mallory-Denk 
bodies. Figure 3 and online supplementary figure 1 
demonstrate steatohepatitis with ballooning of hepato-
cytes and Mallory-Denk bodies.
Fibrosis in fatty liver disease usually affects the peri-
central (zone 3) region first, extending along sinusoids 
and around individual hepatocytes in a ‘chicken-wire’ 
pattern.20 Portal fibrosis is generally seen later in the 
process. Eventually, bridging fibrosis and cirrhosis can 
ensue.
The NAFLD activity score was designed originally 
for consistency of reporting in trials; however, it is 
often used in clinical practice and familiarity with it 
can be helpful.21 The maximum score is 8, with the 
parameters comprising steatosis (0–3), ballooning 
(0–2) and lobular inflammation (0–3). The degree of 
fibrosis is also scored from 1 (mild) to 4 (cirrhosis). 
A more recent Steatosis/Activity/Fibrosis score uses 
an algorithmic approach to designate biopsies as ‘No 
NAFLD’, ‘NAFLD’ or ‘NASH’.22
HepAtItIs
Acute hepatitis
Acute hepatitis usually causes a lobular pattern of inflam-
mation. The inflammation can be mild with minor 
infiltrates and spotty necrosis of single hepatocytes, or 
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Figure 4 Top left—H&E stain showing acute hepatitis with lobular disarray and associated lymphocytic inflammation, acidophil body formation 
(arrow) and bilirubinostasis. Top right—H&E stain showing features of chronic hepatitis in the context of chronic hepatitis B infection. There is a 
moderately dense portal infiltrate comprising predominantly lymphocytes, showing conspicuous interface activity (arrow). L, lobule; P, portal tract. 
Bottom right—H&E stain showing the classical changes of primary biliary cholangitis with a florid granulomatous inflammatory bile duct lesion. The 
residual damaged duct is seen in the centre of the image (arrow). Bottom left—H&E stain showing concentric fibrosis surrounding an inflamed bile 
duct, a typical change of primary sclerosing cholangitis.
in severe cases cause widespread necrosis with archi-
tectural disturbance (lobular disarray) or collapse12 
(see figure 4).
Histologically determining the cause can be difficult: 
possibilities include acute viral infections, drug-in-
duced or toxin-induced hepatitis, an acute presenta-
tion of autoimmune hepatitis (AIH) or ‘seronegative’ 
hepatitis. Serology is generally helpful in the diagnosis 
of viral infections. The presence of an eosinophilic 
inflammatory infiltrate may support drug-induced 
injury, although eosinophils are not specific and can 
be seen in other conditions including AIH.23 Factors 
supporting the diagnosis of AIH include a plasma cell–
rich infiltrate12 and positive immunology.
chronic hepatitis
Chronic hepatitis usually results in a portal distribu-
tion of inflammation, with spill-over into the adjacent 
liver parenchyma (interface hepatitis). A similar differ-
ential exists as for acute hepatitis, namely viral infec-
tions, drug-induced or toxin-induced injury, and AIH. 
A number of other diseases may be associated with 
portal and periportal inflammatory changes, which 
can resemble those seen in chronic viral hepatitis or 
AIH. Examples include chronic biliary diseases such 
as primary biliary cholangitis (PBC) and primary scle-
rosing cholangitis (PSC), fatty liver disease and some 
metabolic diseases (eg, Wilson’s disease and alpha-1 
antitrypsin deficiency). In most of these cases, the 
presence of additional histological features points to 
an alternative diagnosis.
Viral hepatitis
Typically, chronic hepatitis B infection causes histolog-
ical activity in different phases in the natural history 
of the disease, hence a recent change in terminology 
to either chronic hepatitis or chronic infection in 
association with e antigen status.24 Orcein staining 
can demonstrate surface antigen expression, and the 
degree of activity can influence treatment decisions. 
Figure 4 and online supplementary figure 2 demon-
strate chronic hepatitis due to hepatitis B infection. 
Hepatitis C can be associated with steatosis and bile 
duct injury in addition to chronic hepatitis.12 Elastog-
raphy now has a well-established role in the assessment 
of fibrosis in this context.1
Autoimmune hepatitis
AIH is characterised by interface hepatitis, but varying 
degrees of lobular hepatitis can be present. The presence 
of plasma cells in the infiltrate is suggestive of this diag-
nosis. The clustering of regenerating hepatocytes in areas 
of fibrous portal expansion is called a ‘rosette’23 (see 
online supplementary figure 3). Biliary changes are not 
routinely seen in AIH. Liver biopsy plays an important 
role in AIH: establishing the diagnosis, grading disease 
activity and staging the level of fibrosis.25
bIlIAry dIseAse
primary biliary cholangitis
PBC can be diagnosed confidently with biochemical 
cholestasis and supportive immunology (anti-mito-
chondrial antibody positivity or specific ANAs), and 
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hence liver biopsy is not a prerequisite for diagnosis. 
Liver biopsy may be required to establish a diagnosis of 
AMA-negative PBC in cases of unexplained intrahepatic 
cholestasis and can be useful if there are concerns about 
an AIH/PBC overlap syndrome. It is worth noting that 
accurately defining overlap syndromes can be difficult.26
The key finding is a portal inflammatory infiltrate 
with a granulomatous component centred on small 
bile ducts (see figure 4). This is associated with injury 
to the biliary epithelial cells and disruption of the 
bile duct basement membrane.12 Small bile ducts are 
progressively lost (ductopenia).27 Periportal fibrosis 
then ensues and can progress to cirrhosis.
primary sclerosing cholangitis
The histological changes of PSC are variable, and extra-
hepatic bile ducts are not present in needle liver biopsy 
specimens. However, small-duct PSC can be diagnosed 
histologically and some changes may be identified 
reflecting biliary obstruction from downstream large 
bile duct strictures. Portal inflammation can be present 
but is usually less pronounced than in PBC.12 Fibrous 
obliteration of bile ducts can occur; the classical lesion 
is a concentric ‘onion skin’ fibrosis around an affected 
duct28 (see figure 4). In contrast to PBC, granulomas 
are not typically seen.
metAbolIc lIver dIseAse
Hepatic siderosis
Hepatic iron deposition can result from iron overload 
states due to any cause. The most common inher-
ited cause is HFE haemochromatosis. Other condi-
tions causing iron overload include alcohol-related 
liver disease, non-HFE haemochromatosis, ferroportin 
disease and repeated transfusion.29 Liver biopsy is some-
times undertaken in HFE haemochromatosis to deter-
mine the stage of fibrosis, although elastography can 
often achieve this. In cases of suspected iron overload, 
liver biopsy (and MRI) can be used to confirm or refute 
significant hepatic siderosis which can aid diagnosis.30
Accumulation of iron is directly toxic to hepatocytes 
and acts as a stimulus for collagen production.12 Portal 
tracts may show varying degrees of inflammation and 
iron can be deposited in biliary epithelium. Perls’ 
(Prussian blue) stains ferric iron deposits (see figure 3).
Wilson’s disease
Liver biopsy can be undertaken to aid diagnosis 
of Wilson’s disease and quantitative copper assays 
performed.31 Wilson’s disease can present acutely with 
liver failure: biopsies undertaken in this scenario typi-
cally show hepatocyte degeneration and parenchymal 
collapse—interestingly, cirrhosis is often present.12 
In less acute presentations, histological changes can 
be very varied. As changes progress, appearances 
may mimic chronic hepatitis with portal inflamma-
tion, interface hepatitis and fibrosis.32 Importantly, 
increased copper deposits can be seen in cholestasis 
from any cause.12
Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency can present with chronic 
liver disease in a small proportion of patients. It is 
often concomitant with another cause of liver disease. 
Liver biopsy may reveal mild portal inflammation or 
simply non-specific fibrotic changes.12 The periodic 
acid–Schiff (PAS) stain, in combination with diastase to 
digest glycogen (PAS-D), will stain abnormal globules 
of defective alpha-1 antitrypsin within hepatocytes 
(see figure 3).
vAsculAr lIver dIsorders
Hepatic venous outflow obstruction
Liver biopsy is not generally required in the work-up 
of Budd-Chiari syndrome, as the confirmation of 
venous outflow obstruction is usually made via hepatic 
venography. However, biopsy can be carried out 
during venography to clarify the degree of fibrosis. 
Occlusion of the hepatic venules can be seen, in addi-
tion to sinusoidal dilatation and adjacent hepatocyte 
atrophy.33 Erythrocytes may be translocated to the 
space of Disse (see figure 3). Congestive hepatopathy 
due to heart failure or constrictive pericarditis can give 
similar appearances.
obliterative portal venopathy (idiopathic non-cirrhotic 
portal hypertension)
The nomenclature surrounding non-cirrhotic portal 
hypertension (NCPHT) is confusing. There is a range 
of conditions that can cause portal hypertension in 
the absence of significant fibrosis. However, NCPHT 
is usually taken to mean idiopathic NCPHT. This is 
a disease associated with obliterative/sclerotic changes 
to small portal vein branches, and occurs by definition 
in the absence of extrahepatic portal vein thrombosis 
and significant hepatic fibrosis.34 Nodular regenerative 
hyperplasia is one particular histological appearance 
associated with the condition (see online supplemen-
tary figure 4).
trAnsplAntAtIon
Liver biopsy plays an important role in the manage-
ment of liver allograft recipients, where it is often 
performed due to graft dysfunction.
Graft dysfunction in the early postoperative period 
has a variety of causes; biopsy may be helpful to deter-
mine the specific diagnosis or indicate the dominant 
insult. Changes of preservation-reperfusion injury are 
commonly seen and include microvesicular steatosis, foci 
of lobular neutrophilic inflammation, cholestasis, hepato-
cyte ballooning and necrosis.35 Acute cellular rejection 
(ACR) usually occurs in the first month post-transplant. 
Histologically, a portal pattern of injury occurs with a 
mononuclear inflammatory infiltrate and inflammation 
of bile ducts.35 Subendothelial inflammation of portal 
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Table 2 Glossary of common terms and phrases appearing in liver histology reports
Apoptotic body 
(also known as 
Councilman or 
acidophil body)
Hepatocyte undergoing a ‘programmed’ cell death in response to an insult, stains pink on H&E
Ballooning A process associated with degenerating hepatocytes where they swell in size up to twofold or threefold with a ‘wispy’ clear cytoplasm 
often containing Mallory-Denk bodies; associated with steatohepatitis and cholate stasis
Bridging fibrosis Fibrosis extending between adjacent portal tracts or between a portal tract and an adjacent hepatic venule; precursor to cirrhosis
Bilirubinostasis Impaired flow of bile through the biliary system; abnormal amounts of bile can be seen within hepatocytes or bile canaliculi
Ductopenia Reduced numbers of visible bile ducts; can be seen as part of PBC and PSC or can be idiopathic or drug-induced (vanishing bile duct 
syndrome)
Interface hepatitis 
(previously called 
piecemeal necrosis)
Inflammation seen in the border between the portal tracts and the liver parenchyma; a feature of chronic hepatitis
Kupffer cell Star-shaped macrophages found lining sinusoids
Lobule/lobular 
region
A region containing hepatocytes and sinusoids found between portal tracts and hepatic venules
Mallory-Denk body Inclusions found within the cytoplasm of ballooned hepatocytes. Composed of cytokeratin filaments, they have a ‘twisted-rope’ 
appearance
Onion-skin fibrosis Concentric fibrosis around a bile duct; seen in PSC
Portal tract Structure containing a branch of the hepatic artery and portal vein and a bile duct
 Satellitosis Inflammatory cells (neutrophils) surrounding a hepatocyte; seen in alcoholic hepatitis
Sinusoid A sinusoidal blood vessel separated from hepatocytes by the space of Disse; location of mixing of portal and arterial blood
Steatosis Abnormal fat deposition within hepatocytes (>5%)
PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
and hepatic venules is also seen (see online supplemen-
tary figure 5). Zone 3 necroinflammatory changes reflect 
greater severity, with the Banff criteria used for grading.36 
Acute antibody-mediated rejection (AMR) may be asso-
ciated with histological changes resembling those found 
in biliary obstruction37; positive C4d staining may 
support a diagnosis of AMR38 and serum can be analysed 
for donor-specific antibodies. Other causes of early graft 
dysfunction include drug-induced liver injury and acute 
hepatitis due to viral infections such as cytomegalovirus. 
Vascular and biliary problems are also common causes of 
graft dysfunction, usually diagnosed by imaging.
Graft dysfunction in the late postoperative period may 
be due to viral infections, drug-induced injury, recurrent 
disease, ‘de-novo’ disease and rejection. Imaging remains 
important to assess the graft vasculature and biliary tree. 
Chronic rejection usually results from non-resolving or 
repeated episodes of ACR; indeed, changes of both ACR 
and chronic rejection can coexist.39 Histological changes 
of chronic rejection are potentially irreversible and can 
lead to graft loss in severe cases.40 There may be improve-
ment with augmented immunosuppression. The key 
finding in chronic rejection is ductopenia (without the 
active portal inflammation seen in ACR) and loss of small 
branches of the hepatic artery, in addition to varying 
degrees of perivenular fibrosis39 (see online supplemen-
tary figure 6).
future dIrectIon
While patterns of disease and the indications for liver 
biopsy may be changing, histological analysis of liver 
tissue seems likely to remain an important investiga-
tion. Perhaps one future direction where liver biopsy 
may evolve is automated fibrosis assessment, with 
computer analysis demonstrated to improve scoring 
accuracy and outperform collagen proportionate area 
assessment in recent studies.41 42 As a final point, it is 
worth remembering that it is imperative to include 
relevant clinical details for the histopathologist so they 
can give an informed opinion, and clinicopathological 
correlation is always of paramount importance.
glossAry
The following words appear commonly in histology 
reports (table 2).
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